E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/8/2019 in the Prospect News Convertibles Daily.

Morning Commentary: Stanley Black & Decker mandatory ‘trades well’; Cytokinetics drags

By Rebecca Melvin

New York, Nov. 8 – Stanley Black & Decker Inc.’s newly priced 5.25% mandatory convertible lifted on its trading debut on Friday after the New Britain, Conn.-based maker of hand and power tools priced $675 million of the three-year paper at mixed terms compared to talk.

The new Stanley Black & Decker mandatory was quoted at 102 bid, 102.5 offered, with the common stock at about $157.45.

The deal is “trading well,” a New York-based market source said, adding that it was well received by the market because it is a rated, registered, listed entity that investors have owned in the past, and given the fact that the issuer is a well-known brand name. “It checks all the boxes.”

Pricing of the Stanley Black & Decker paper came at mixed terms compared to revised talk, or at the rich end of 5.25% to 5.5% dividend talk and the cheap end of 20% to 25% premium talk. The deal was initially talked at 5.5% to 6% dividend and 15% to 20% threshold appreciation premium.

The newly priced and upsized Cytokinetics Inc. convertible dragged below par on its debut in market trading on Friday as the underlying shares extended losses after a 19% plunge on Thursday.

The new Cytokinetics 4% notes traded with a 99 handle after the South San Francisco, Calif.-based biopharmaceutical company priced an upsized $120 million of the seven-year notes.

Originally, the Securities and Exchange Commission-registered deal was expected to be $100 million in size. The notes priced at par with an initial conversion premium of 27.5%.

Shares fell to below $8.00 on Friday from around $11.00 before the convertible deal was announced.

In trading among the established secondary market, the 0.75% convertibles of LivePerson Inc. tanked in tandem with a slide in the underlying shares of the developer of conversational commerce and AI software.

Shares of the New York-based company sank $6.65, or 16.5%, to $33.76 as the LivePerson convertibles due 2024 dropped nearly 12 points to 115.35, according to Trace data.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.